Literature DB >> 8865076

Natriuretic effect of non-pressor doses of endothelin-1 in conscious dogs.

N C Sandgaard1, P Bie.   

Abstract

1. Renal, endocrine and haemodynamic responses to separate intravenous infusions of three doses of endothelin-1 (40, 400 and 4000 fmol kg-1 min-1) were investigated in conscious dogs. 2. Administration of 40, 400 and 4000 fmol kg-1 min-1 endothelin-1 for 120 min increased plasma endothelin-1 levels by two-, seven- and 250-fold, respectively. 3. The two low doses did not have measurable effects on mean arterial blood pressure and heart rate but tended to increase glomerular filtration rate. The high dose increased mean arterial blood pressure (MABP; from 104 +/- 4 to 138 +/- 4 mmHg, P < 0.05) and decreased heart rate (from 71 +/- 4 to 46 +/- 3 beats min-1, P < 0.05) as well as glomerular filtration rate (from 47 +/- 3 to 19 +/- 5 ml min-1, P < 0.05). 4. At rates of 40 and 400 fmol kg-1 min-1, endothelin-1 increased sodium excretion about five- and eightfold, respectively. Relative changes in fractional sodium excretion were very similar. The high dose was markedly antinatriuretic (reducing sodium excretion from 8.3 +/- 1.1 to 1.2 +/- 0.2 mumol min-1, P < 0.05). 5. Diuresis increased during the administration of the two lower doses, which did not change plasma atrial natriuretic peptide or vasopressin concentrations. Urine flow increased after termination of the infusion of the pressor dose despite elevated plasma vasopressin and subnormal glomerular filtration rate. 6. Infusion of endothelin-1 at 40 fmol kg-1 min-1 did not change the concentrations of angiotensin II and atrial natriuretic peptide in plasma. Infusion of 400 fmol kg-1 min-1 was associated with a decrease in plasma angiotensin II, while plasma atrial natriuretic peptide was unchanged. The high dose of endothelin-1 markedly increased plasma levels of both hormones. 7. It is concluded that endothelin-1 at low plasma concentrations increases sodium excretion while a higher pressor dose of endothelin-1 is antinatriuretic. However, increases in plasma endothelin-1 seem to elicit diuresis over a wide concentration range, although possibly by different mechanisms.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8865076      PMCID: PMC1160679          DOI: 10.1113/jphysiol.1996.sp021534

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  30 in total

1.  Natriuresis caused by increased carotid Na+ concentration after renal denervation.

Authors:  C Emmeluth; K L Goetz; C Drummer; R Gerzer; W G Forssmann; P Bie
Journal:  Am J Physiol       Date:  1996-03

2.  Cardiovascular, renal, and endocrine responses to intravenous endothelin in conscious dogs.

Authors:  K L Goetz; B C Wang; J B Madwed; J L Zhu; R J Leadley
Journal:  Am J Physiol       Date:  1988-12

3.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

4.  Central venous pressure--a physiological stimulus for secretion of atrial natriuretic peptide in humans?

Authors:  H J Schütten; A C Johannessen; C Torp-Pedersen; K Sander-Jensen; P Bie; J Warberg
Journal:  Acta Physiol Scand       Date:  1987-10

5.  Plasma renin concentration measured by use of radioimmunoassay for angiotensin I.

Authors:  J Giese; M Jörgensen; M D Nielsen; J O Lund; O Munck
Journal:  Scand J Clin Lab Invest       Date:  1970-12       Impact factor: 1.713

6.  Endothelin and sarafotoxin produce dissimilar effects on renal blood flow, but both block the antidiuretic effects of vasopressin.

Authors:  K Goetz; B C Wang; R Leadley; J L Zhu; J Madwed; P Bie
Journal:  Proc Soc Exp Biol Med       Date:  1989-09

7.  Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways.

Authors:  K F Badr; J J Murray; M D Breyer; K Takahashi; T Inagami; R C Harris
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

8.  Endothelin: a potent renal and systemic vasoconstrictor peptide.

Authors:  A J King; B M Brenner; S Anderson
Journal:  Am J Physiol       Date:  1989-06

9.  Studies of cerebral osmoreceptors in anesthetized dogs: the effect of intravenous and intracarotid infusion of hyper-osmolar sodium chloride solutions during sustained water diuresis.

Authors:  P Bie
Journal:  Acta Physiol Scand       Date:  1976-03

10.  Endothelin is a potent secretagogue for atrial natriuretic peptide in cultured rat atrial myocytes.

Authors:  Y Fukuda; Y Hirata; H Yoshimi; T Kojima; Y Kobayashi; M Yanagisawa; T Masaki
Journal:  Biochem Biophys Res Commun       Date:  1988-08-30       Impact factor: 3.575

View more
  6 in total

1.  Endothelin-1 mediates natriuresis but not polyuria during vitamin D-induced acute hypercalcaemia.

Authors:  Natsuko Tokonami; Lydie Cheval; Isabelle Monnay; Guillaume Meurice; Johannes Loffing; Eric Feraille; Pascal Houillier
Journal:  J Physiol       Date:  2017-03-23       Impact factor: 5.182

2.  Endothelin as a causative factor of blunted volume reflex in diabetic rats.

Authors:  Orawan Wongmekiat; Edward J Johns
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

3.  Contribution of endothelin A receptors in endothelin 1-dependent natriuresis in female rats.

Authors:  Daisuke Nakano; David M Pollock
Journal:  Hypertension       Date:  2008-12-22       Impact factor: 10.190

4.  Renal medullary ETB receptors produce diuresis and natriuresis via NOS1.

Authors:  Daisuke Nakano; Jennifer S Pollock; David M Pollock
Journal:  Am J Physiol Renal Physiol       Date:  2008-02-27

5.  Urinary excretion of endothelin-1 in children with absorptive idiopathic hypercalciuria.

Authors:  Polyxeni Nicolaidou; Helen Georgouli; Vasiliki Getsi; Helen Tsapra; Fotini Psychou; Yiannis G Matsinos; Petros M Zeis; Dimitris Gourgiotis
Journal:  Pediatr Nephrol       Date:  2003-10-02       Impact factor: 3.714

6.  Pharmacodynamic Impact of Carboxylesterase 1 Gene Variants in Patients with Congestive Heart Failure Treated with Angiotensin-Converting Enzyme Inhibitors.

Authors:  Karl Emil Nelveg-Kristensen; Peter Bie; Laura Ferrero; Ditte Bjerre; Niels E Bruun; Martin Egfjord; Henrik B Rasmussen; Peter R Hansen
Journal:  PLoS One       Date:  2016-09-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.